DXSE:F:F-Xtrackers Stoxx Europe 600 Health Care Swap UCITS ETF 1C (EUR)

ETF | Others |

Last Closing

USD 236.7

Change

-1.25 (-0.53)%

Market Cap

N/A

Volume

159.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.08 (+0.30%)

USD 139.20B
PRAJ:F Amundi Index Solutions - Amund..

+0.08 (+0.30%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.09%)

USD 115.53B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.09%)

USD 115.53B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 57.94B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 57.94B

ETFs Containing DXSE:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.77% 75% C 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.77% 72% C 61% D-
Trailing 12 Months  
Capital Gain 16.74% 58% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.74% 54% F 54% F
Trailing 5 Years  
Capital Gain 66.29% 79% B- 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.29% 79% B- 63% D
Average Annual (5 Year Horizon)  
Capital Gain 9.06% N/A N/A 68% D+
Dividend Return 9.06% N/A N/A 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.73% N/A N/A 91% A-
Risk Adjusted Return 103.73% N/A N/A 96% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike